Objectives: Fosfomycin penetrates well into cerebrospinal fluid (CSF) and is considered for treatment of infections of the central nervous system (CNS). This study evaluated the influence of human CSF on the antimicrobial activity of fosfomycin.
Introduction
While numerous studies have identified antibiotics that penetrate the blood -brain barrier little attention has been directed to the influence of cerebrospinal fluid (CSF) on antimicrobial activity. However, relating antibiotic CSF concentrations to the MICs determined in broth may be misleading because CSF can affect bacterial growth and killing. 1, 2 Fosfomycin has a relatively low molecular mass (138.1) and acts by inhibiting the UDP-N-acetylglucosamine-enolpyruvyltransferase required for the synthesis of murein for the bacterial cell wall. The fosfomycin concentrations measured in CSF of patients with extraventricular drainage-associated infections at steady state (mean C max 62+38 mg/L) were considered sufficient for therapy of common CSF infections. 3 To test this assumption we evaluated the influence of human CSF on the activity of fosfomycin in vitro.
Methods

Media and strains
Remnants of $300 CSF samples from patients who did not receive antibiotics were collected, pooled and sterile-filtered. MuellerHinton broth (MHB) was supplemented with glucose-6-phosphate (G-6-P the pharmacokinetic/pharmacodynamic (PK/PD) simulation, representing a previously reported MIC 50 value. 4 
Static time -kill curves
Bacterial time-kill curves were performed in MHB, in CSF in ambient air and in CSF in air with 5% CO 2 using fosfomycin concentrations below and above the MIC. CO 2 served to maintain physiological pH in CSF. 2, 5 PK/PD simulation
To estimate bacterial killing at the target site in the worst case, the PK profile of a ventriculitis patient with the lowest drug concentrations in CSF at steady state in a previous study (broken line in Figure 1c ) was simulated. 3 In the CSF of this patient the AUC 0 -8 was 112 mg . h/L and the half-life was 8.7 h after multiple doses of 8 g of fosfomycin every 8 h. Test strains were exposed to the selected PK profile in vitro in CSF in air with 5% CO 2 . Rising drug concentrations were obtained by addition of fosfomycin, and falling concentrations by addition of CSF. Bacterial counts were determined over time and back-extrapolated to the original volume to account for the respective dilution.
Results and discussion
The media used had a major influence on bacterial growth and killing of fosfomycin. In MHB sustained bactericidal effects were achieved at 1Â MIC (Figure 1a ). In CSF with 5% CO 2 killing occurred between baseline and 8 h at fosfomycin concentrations of 1Â MIC or higher, but bacterial re-growth was detected at 1Â to 4Â MIC after 24 h (Figure 1b) . To achieve sustained killing 8Â MIC was required in CSF with 5% CO 2 . In CSF without CO 2 even at 8Â MIC fosfomycin had no relevant antimicrobial effect because its activity is impaired at higher pH (not shown).
When the concentration -time curve of the selected patient was simulated in vitro in CSF fosfomycin was bactericidal to SA 2 during the first hours of the experiment (Figure 1c) . After 24 h marked re-growth was detected although the fosfomycin concentrations fluctuated between $5Â and 16Â MIC. Both bacterial killing and growth of SA 16 were marginal compared with SA 2. This is comprehensible because the simulated fosfomycin concentrations corresponded to 0.7Â to 2Â MIC, a range that was also insufficient in the static time -kill curves in CSF. Thus, time-kill curves and PK/PD simulations suggest that the fosfomycin concentrations in CSF must exceed at least 8Â MIC during the entire dosing interval to obtain a lasting reduction of S. aureus. This is in agreement with previous studies reporting that fosfomycin monotherapy is effective in rabbit meningitis caused by Streptococcus pneumoniae, only if a minimum concentration of 8Â to 10Â MIC is constantly achieved at the target site. 6, 7 The analogous results of the rabbit studies with our in vitro experiments suggest that bacterial time-kill curves may predict the magnitude of antibiotic concentrations needed in vivo in the CNS if they are performed in pH-adjusted CSF.
Lower growth rates may be responsible for reduced antimicrobial activity in CSF because fosfomycin inhibits synthesis of the bacterial cell wall, and its activity was assumed to be growth and time dependent, rather than concentration dependent. 3, 8 Also the lack of G-6-P may explain reduced activity, but as G-6-P is not detectable in human CSF it was not added in the experiment. 9 Considering the fosfomycin concentrations reported for human CSF at steady state, 3 CNS infections caused by strains for which the MIC is !4 mg/L may hardly be treated with fosfomycin. Anyway, fosfomycin is combined with other antimicrobial agents in clinical practice to avoid emergence of resistant isolates. In experimental meningitis fosfomycin enhanced the efficacy of vancomycin or ceftriaxone. 7 Among other limitations, the present study investigated neither changing nutrient and G-6-P concentrations in CSF, nor various bacterial species and combinations of fosfomycin with other antibiotics.
Summarizing, the activity of fosfomycin against S. aureus is notably reduced in human CSF, and drug concentrations constantly exceeding a multiple of the MIC are required to achieve sustained antimicrobial effects.
